COVID-19 isn’t the world’s first pandemic. Nor will it be the last — unless we bring together the world’s best scientific minds and give them the resources to stop the next virus from becoming a global catastrophe.

READDI is guided by world-leading authorities.

This global nonprofit initiative brings together leaders from industry, government, philanthropic organizations and academic research institutions. Expertise for antiviral development is spread across the world, and any effort to rapidly and efficiently develop novel drugs needs to tap into the power of this network.

Collaborating for a safer future.

READDI is retooling the drug discovery and development process to rapidly develop new broad-spectrum antiviral drug solutions for the future. These pandemics are bigger than any one university, company or government. A unique public-private partnership accelerated by a global access model, READDI has a goal of developing multiple “on the shelf” clinical assets so that we are prepared for the next global health pandemic.

Antiviral Innovation Engine

Universities

Foundations

Philanthropists

Government

Pharmaceutical Industries

Through our open access model, READDI will accelerate the pace of antiviral discovery globally for three viral families with the most pandemic potential — coronaviruses, flaviviruses and alphaviruses. 

Learn More

Meet the team who makes us READDI.

Founding Partners

READDI began with a groundbreaking collaboration between the University of North Carolina (UNC)-Chapel Hill, the UNC Eshelman Institute for Innovation (EII) and the Structural Genomics Consortium (SGC).

READDI Leadership

We are led by a decorated team of the world's brightest research minds.